Understanding SMA Experiences in MedStar Health
This observational study aims to understand the diagnostic journey, patient experiences, and treatment differences for people with Spinal Muscular Atrophy (SMA) within the MedStar Health System. We want to learn more about how people with SMA are diagnosed, their experiences with treatments like nusinersen (Spinraza), onasemnogene abeparvovec-xioi (Zolgensma), and risdiplam (Evrysdi), and any challenges they face. We are looking for adults (18 years or older) who have an SMA diagnosis. The main goal is to find out how many SMA patients are not receiving disease-modifying therapy and why, based on surveys with patients or their caregivers. The study status is currently unclear.
- Study design
- This is an observational study with a planned enrollment of 200 participants. It involves reviewing medical records and conducting telephone interviews.
- What's involved
- If you are eligible, you may be invited to participate in a one-time telephone interview lasting about 60 minutes.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint data will be measured between 2020 and 2025.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Proportion of SMA patients not receiving disease-modifying therapy and categorical causes for non-treatment based on structured patient/caregiver survey responses2020-2025
The primary outcome assesses the percentage of patients with a confirmed diagnosis of spinal muscular atrophy (SMA) who are not currently receiving an FDA-approved disease-modifying therapy (nusinersen, risdiplam, or onasemnogene abeparvovec). Data are collected through a structured telephone or in-person survey using the Lost to Follow-Up Interview Questionnaire, designed to identify categorical reasons for non-treatment. Categories include insurance or financial barriers, clinical contraindications, patient preference, adverse effects, loss to follow-up, or access limitations. The outcome will quantify the proportion of patients in each category to identify predominant causes of non-treatment and guide future outreach and care re-engagement strategies. Unit of Measure: Percentage of participants.